A citation-based method for searching scientific literature

Sijin Duan, Lin Dong, Bingsi Wang, Shujuan Wei, Xiaoyan Gong, Pengfei Yu, Chunmei Li, Yonglin Gao, Liang Ye, Hongbo Wang, Jingwei Tian. Regul Toxicol Pharmacol 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The impact of translocations and gene fusions on cancer causation.
Felix Mitelman, Bertil Johansson, Fredrik Mertens. Nat Rev Cancer 2007
833
100

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.
A Vaishnavi, M Capelletti, A T Le, S Kako, M Butaney, D Ercan, S Mahale, K D Davies, D L Aisner, A B Pilling,[...]. Nat Med 2013
352
100

(R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors.
Ha-Soon Choi, Paul V Rucker, Zhicheng Wang, Yi Fan, Pamela Albaugh, Greg Chopiuk, Francois Gessier, Fangxian Sun, Francisco Adrian, Guoxun Liu,[...]. ACS Med Chem Lett 2015
25
100

PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression in vitro and in vivo.
Fangfang Li, Zongliang Liu, Heyuan Sun, Chunmei Li, Wenyan Wang, Liang Ye, Chunhong Yan, Jingwei Tian, Hongbo Wang. Acta Pharm Sin B 2020
11
100

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types.
Alessio Amatu, Andrea Sartore-Bianchi, Salvatore Siena. ESMO Open 2016
231
100

TRKing down an old oncogene in a new era of targeted therapy.
Aria Vaishnavi, Anh T Le, Robert C Doebele. Cancer Discov 2015
289
100

Rearrangements of NTRK1 gene in papillary thyroid carcinoma.
A Greco, C Miranda, M A Pierotti. Mol Cell Endocrinol 2010
115
100

The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.
Elena Ardini, Roberta Bosotti, Andrea Lombardi Borgia, Cristina De Ponti, Alessio Somaschini, Rosaria Cammarota, Nadia Amboldi, Laura Raddrizzani, Andrea Milani, Paola Magnaghi,[...]. Mol Oncol 2014
93
100

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
Alexander Drilon, Ramamoorthy Nagasubramanian, James F Blake, Nora Ku, Brian B Tuch, Kevin Ebata, Steve Smith, Veronique Lauriault, Gabrielle R Kolakowski, Barbara J Brandhuber,[...]. Cancer Discov 2017
177
100


Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
918
100

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J Lin, Viola W Zhu, Myung-Ju Ahn, D Ross Camidge, Judy Nguyen,[...]. Cancer Discov 2018
139
100


Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
Elena Ardini, Maria Menichincheri, Patrizia Banfi, Roberta Bosotti, Cristina De Ponti, Romana Pulci, Dario Ballinari, Marina Ciomei, Gemma Texido, Anna Degrassi,[...]. Mol Cancer Ther 2016
142
100

Larotrectinib (LOXO-101).
Stephanie Berger, Uwe M Martens, Sylvia Bochum. Recent Results Cancer Res 2018
11
100

Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data.
Nameeta Shah, Michael Lankerovich, Hwahyung Lee, Jae-Geun Yoon, Brett Schroeder, Greg Foltz. BMC Genomics 2013
49
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.